Cargando…

Sertoli–Leydig cell tumors of ovary: A case series

INTRODUCTION: The purpose of this study was to report the clinical features, computed tomography (CT) and magnetic resonance imaging (MRI) findings, clinical management, and prognoses of 7 patients with Sertoli–Leydig cell tumors (SLCT) of ovary, and to review the literature of this rare condition....

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Qiong, Zou, Yu, Zhang, Xiao Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211859/
https://www.ncbi.nlm.nih.gov/pubmed/30334998
http://dx.doi.org/10.1097/MD.0000000000012865
_version_ 1783367418905624576
author Xu, Qiong
Zou, Yu
Zhang, Xiao Fei
author_facet Xu, Qiong
Zou, Yu
Zhang, Xiao Fei
author_sort Xu, Qiong
collection PubMed
description INTRODUCTION: The purpose of this study was to report the clinical features, computed tomography (CT) and magnetic resonance imaging (MRI) findings, clinical management, and prognoses of 7 patients with Sertoli–Leydig cell tumors (SLCT) of ovary, and to review the literature of this rare condition. METHODS: Seven patients with pathologically confirmed ovarian SLCT were included. Their clinical, CT and MRI characteristics (CT images obtained from 6 patients and MR images from 4 patients), clinical management, and prognoses of 7 patients were retrospectively analyzed. RESULTS: Patients symptoms included irregular menstruation (n = 3), infertile (n = 1), vaginal bleeding after 7 years of menopause (n = 1), a palpable abdominal mass (n = 1), and abdominal pain (n = 1). Three patients had elevated alpha-fetoprotein (AFP), 1 had elevated cancer antigen 125 (CA125), and 2 had elevated Testosterone (T). The 7 tumors of 7 patients were solid or mixed solid-cystic mass with clear boundaries. The solid components of the tumors showed iso-dense on CT. On MRI, the solid components showed iso- or slightly low signal intensity (SI) on T1-weighted imaging (T1WI), high or slightly high SI on T2WI, and high on diffusion-weighted imaging (DWI) with low apparent diffusion coefficient (ADC) value. On contrast-enhanced CT and MRI, 1 tumor exhibited heterogeneous enhancement consisting of multiple nodules with relatively marked homogeneous enhancement, and other 6 tumors showed moderate or marked and constantly heterogeneous enhancements. All patients were treated with surgical excision. Only 3 had received postoperative chemotherapy. With the exception of 1 patient lost to follow-up, the other 6 patients exhibited tumor-free survival with a median follow-up time of 13.5 months, the longest follow-up time being 24 months. CONCLUSION: The patients of SLCT can present with hormonal magnification and manifest high AFP, CA125, and T levels. SLCT is characterized by a solid or mixed solid-cystic mass on CT/MR scans, and shows marked or moderated heterogeneous and constantly enhancement upon postcontrast study. The clinical characteristics and imaging findings are features and appropriated imaging should be performed whenever an SLCT is suspected.
format Online
Article
Text
id pubmed-6211859
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-62118592018-11-27 Sertoli–Leydig cell tumors of ovary: A case series Xu, Qiong Zou, Yu Zhang, Xiao Fei Medicine (Baltimore) Research Article INTRODUCTION: The purpose of this study was to report the clinical features, computed tomography (CT) and magnetic resonance imaging (MRI) findings, clinical management, and prognoses of 7 patients with Sertoli–Leydig cell tumors (SLCT) of ovary, and to review the literature of this rare condition. METHODS: Seven patients with pathologically confirmed ovarian SLCT were included. Their clinical, CT and MRI characteristics (CT images obtained from 6 patients and MR images from 4 patients), clinical management, and prognoses of 7 patients were retrospectively analyzed. RESULTS: Patients symptoms included irregular menstruation (n = 3), infertile (n = 1), vaginal bleeding after 7 years of menopause (n = 1), a palpable abdominal mass (n = 1), and abdominal pain (n = 1). Three patients had elevated alpha-fetoprotein (AFP), 1 had elevated cancer antigen 125 (CA125), and 2 had elevated Testosterone (T). The 7 tumors of 7 patients were solid or mixed solid-cystic mass with clear boundaries. The solid components of the tumors showed iso-dense on CT. On MRI, the solid components showed iso- or slightly low signal intensity (SI) on T1-weighted imaging (T1WI), high or slightly high SI on T2WI, and high on diffusion-weighted imaging (DWI) with low apparent diffusion coefficient (ADC) value. On contrast-enhanced CT and MRI, 1 tumor exhibited heterogeneous enhancement consisting of multiple nodules with relatively marked homogeneous enhancement, and other 6 tumors showed moderate or marked and constantly heterogeneous enhancements. All patients were treated with surgical excision. Only 3 had received postoperative chemotherapy. With the exception of 1 patient lost to follow-up, the other 6 patients exhibited tumor-free survival with a median follow-up time of 13.5 months, the longest follow-up time being 24 months. CONCLUSION: The patients of SLCT can present with hormonal magnification and manifest high AFP, CA125, and T levels. SLCT is characterized by a solid or mixed solid-cystic mass on CT/MR scans, and shows marked or moderated heterogeneous and constantly enhancement upon postcontrast study. The clinical characteristics and imaging findings are features and appropriated imaging should be performed whenever an SLCT is suspected. Wolters Kluwer Health 2018-10-19 /pmc/articles/PMC6211859/ /pubmed/30334998 http://dx.doi.org/10.1097/MD.0000000000012865 Text en Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
spellingShingle Research Article
Xu, Qiong
Zou, Yu
Zhang, Xiao Fei
Sertoli–Leydig cell tumors of ovary: A case series
title Sertoli–Leydig cell tumors of ovary: A case series
title_full Sertoli–Leydig cell tumors of ovary: A case series
title_fullStr Sertoli–Leydig cell tumors of ovary: A case series
title_full_unstemmed Sertoli–Leydig cell tumors of ovary: A case series
title_short Sertoli–Leydig cell tumors of ovary: A case series
title_sort sertoli–leydig cell tumors of ovary: a case series
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211859/
https://www.ncbi.nlm.nih.gov/pubmed/30334998
http://dx.doi.org/10.1097/MD.0000000000012865
work_keys_str_mv AT xuqiong sertolileydigcelltumorsofovaryacaseseries
AT zouyu sertolileydigcelltumorsofovaryacaseseries
AT zhangxiaofei sertolileydigcelltumorsofovaryacaseseries